Tygacil 50mg Injection (Tigecycline) is a broad-spectrum glycylcycline antibiotic indicated for the treatment of complicated skin and soft tissue infections (cSSTIs), complicated intra‑abdominal infections (cIAIs), and community‑acquired pneumonia (CAP) when other options aren’t viable. Each vial contains 50 mg of Tigecycline for intravenous infusion, and this pack includes 10 single‑use vials—ideal for hospital settings where multi-dose therapy is required.

Tigecycline works by inhibiting bacterial protein synthesis, targeting a broad range of gram-positive, gram-negative, and anaerobic pathogens—even those resistant to other antibiotics. Doctors typically prescribe Tygacil for hospital-acquired infections, particularly when multidrug-resistant organisms like MRSA, VRE, or ESBL‑producing bacteria are suspected.

Administer Tygacil via slow IV infusion over 30–60 minutes. The initial dose is 100 mg, followed by 50 mg every 12 hours. Dosage may be adjusted for patients with hepatic impairment or severe illness. Healthcare providers administer the treatment in clinical settings with careful monitoring of liver function and signs of bacterial response.

Common side effects include nausea, vomiting, diarrhea, and infusion site reactions. Serious risks like pancreatitis, liver enzyme elevation, or severe arrhythmias require prompt medical attention.

Store vials between 2 °C and 8 °C. Keep them in original packaging to protect from light and moisture. Use within the expiry date and discard unused portions.